Screening Novel TAAbs based on Proteomic Chip and Evaluating the Performance of Them in the Diagnosis of Esophageal Squamous cell carcinoma
作者单位：College of Public Health Zhengzhou University
会议名称：《2021年中国肿瘤标志物学术大会暨第十五届肿瘤标志物青年科学家论坛》
会议日期：2021年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
关 键 词：esophageal squamous cell carcinoma(ESCC) proteomic chip tumor-associated antigen autoantibodies diagnosis model
摘 要：Aim: Esophageal cancer(EC)is one of the common malignant tumors in the world, and its incidence and mortality are relatively high. Global cancer statistics released in 2020 showed that EC has a higher incidence in East Asia, especially in China, and males are significantly higher than females. The number of new cases of EC in China in 2020 was about 324,422, accounting for about 50% of the world;the number of deaths was 301,135, accounting for about 55% of the world. According to the clinical histopathological type, EC was mainly divided into esophageal adenocarcinoma(EAC) and esophageal squamous cell carcinoma(ESCC). Importantly, the incidence of ESCC in China accounts for more than 70% of the world. The onset of ESCC was insidious and there were no obvious clinical symptoms in the early stage. At present, the pathogenesis of ESCC was not clear, and there was lack of effective treatment measures for advanced ESCC patients. Therefore, finding a noninvasive diagnostic method for ESCC of early stage is crucial to improve the 5-year survival rate of *** years, many studies have found that autoantibodies against tumor-associated antigen(TAAbs)can be used as biomarkers in the diagnosis of esophageal squamous cell carcinoma(ESCC). The aim of this study is to screen novel TAAbs through proteomic chip and constructing a diagnostic model to discriminate ESCC cases from benign esophageal diseases(BED) cases and healthy controls(HCs).Methods: HuProt human proteomic chip was purchased from BCBIO Biotechnology(Guangzhou,China). The chip is currently the world’s largest collection of full-length human proteins available. It contains more than 21,000 recombinant proteins and covers all human recombinant proteins that can be purified, covering 81% of the human proteome. The human proteomic chip was used to screen TAAbs. Enzyme-linked immunosorbent assay(ELISA) was used to verify and validate the candidate TAAbs screened by the chip in cohort 1(90 ESCC cases and 90 HCs)